The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

被引:58
作者
Steffensen, K. D.
Waldstrom, M.
Jeppesen, U.
Jakobsen, E.
Brandslund, I.
Jakobsen, A.
机构
[1] Vejle Hosp, Dept Oncol, DK-7100 Vejle, Denmark
[2] Horsens Hosp, Dept Gynecol & Obstet, Horsens, Denmark
[3] Univ So Denmark, Inst Reg Hlth Sci, Odense, Denmark
[4] Vejle Hosp, Dept Clin Biochem, Vejle, Denmark
[5] Vejle Hosp, Dept Pathol, Vejle, Denmark
关键词
COX2; HER2; amplification; overexpression; ovarian cancer; prognostic marker;
D O I
10.1111/j.1525-1438.2006.00855.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both cyclooxygenase 2 (COX2) and human epidermal growth factor receptor 2 (HER2, also called c-erbB-2) overexpression have been related to a worse prognosis in epithelial ovarian cancer (EOC), but the data are conflicting and the percentage of tumors with overexpression varies widely in different studies. The aim of this study was to investigate the potential prognostic value of COX2 and HER2 expression in EOC. A further purpose was to investigate a possible coexpression of the two markers, and finally, to elucidate the agreement between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for evaluation of the HER2 status in EOC. Immunostaining was performed for COX2/HER2 together with FISH analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages IIB-IV. Follow-up was more than 10 years. COX2 overexpression was found in 20.0% of the tumors. With HER2 staining, 64.4% were scored as 0, 24.4% as 1+, 6.9% as 2+, and 4.4% as 3+. Median survival time for COX2-negative tumors was 21.6 versus 36 months for COX2-positive tumors. The longer survival for COX2 positive was significant by both univariate analysis (P = 0.015) and multivariate analysis (P = 0.025). Positive immunostaining for HER2 was associated with poor overall survival (P = 0.03). Agreement between IHC and FISH was seen in all cases (P < 0.0000001). With long-term observation, patients with negative COX2 expression had significantly shorter survival compared to patients with COX2-positive tumors. Positive HER2 expression also notified a grave prognosis, but the low rate of overexpression reduces its potential clinical application.
引用
收藏
页码:798 / 807
页数:10
相关论文
共 46 条
[1]   Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival [J].
Ali-Fehmi, R ;
Morris, RT ;
Bandyopadhyay, S ;
Che, MX ;
Schimp, V ;
Malone, JM ;
Munkarah, AR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (03) :819-825
[2]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[3]   Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].
Bookman, MA ;
Darcy, KM ;
Clarke-Pearson, D ;
Boothby, RA ;
Horowitz, IR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290
[4]   Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells [J].
Coffey, RJ ;
Hawkey, CJ ;
Damstrup, L ;
GravesDeal, R ;
Daniel, VC ;
Dempsey, PJ ;
Chinery, R ;
Kirkland, SC ;
DuBois, RN ;
Jetton, TL ;
Morrow, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :657-662
[5]   Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma [J].
Denkert, C ;
Köbel, M ;
Pest, S ;
Koch, I ;
Berger, S ;
Schwabe, M ;
Siegert, A ;
Reies, A ;
Klosterhalfen, B ;
Hauptmann, S .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (03) :893-903
[6]   Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma [J].
Erkinheimo, TL ;
Lassus, H ;
Finne, P ;
van Rees, BP ;
Leminen, A ;
Ylikorkala, O ;
Haglund, C ;
Butzow, R ;
Ristimäki, A .
CLINICAL CANCER RESEARCH, 2004, 10 (02) :538-545
[7]   C-ERBB2 GENE AMPLIFICATION AND PROTEIN EXPRESSION IN OVARIAN EPITHELIAL TUMORS - EVALUATION OF THEIR RESPECTIVE PROGNOSTIC-SIGNIFICANCE BY MULTIVARIATE-ANALYSIS [J].
FAJAC, A ;
BENARD, J ;
LHOMME, C ;
REY, A ;
DUVILLARD, P ;
ROCHARD, F ;
BERNAUDIN, JF ;
RIOU, G .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (02) :146-151
[8]  
FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO
[9]  
2-8
[10]   Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients [J].
Ferrandina, G ;
Lauriola, L ;
Zannoni, GF ;
Fagotti, A ;
Fanfani, F ;
Legge, F ;
Maggiano, N ;
Gessi, M ;
Mancuso, S ;
Ranelletti, FO ;
Scambia, G .
ANNALS OF ONCOLOGY, 2002, 13 (08) :1205-1211